Variation in parathyroid hormone immunoassay results--a critical governance issue in the management of chronic kidney disease.
Renal physicians strive to maintain parathyroid hormone (PTH) concentrations for patients with chronic kidney disease (CKD) within guideline limits, but poor method comparability means there is currently serious risk of clinical misclassification. The potential for under- or over-treatment is significant, representing a major challenge to patient safety. In the short-term, raising awareness of clinical implications of method-related differences in PTH is essential. Agreeing and adopting assay-specific PTH action limits for CKD patients as an interim measure is highly desirable and has been achieved in Scotland. Establishing pre-analytical requirements for PTH is also a priority. In the longer term, re-standardization of PTH methods in terms of an appropriate International Standard is required. Provided commutability can be demonstrated, the recently established IS 95/646 for PTH (1-84) is a suitable candidate. Establishment of a well-characterized panel of samples of defined clinical provenance to enable manufacturers to determine appropriate reference intervals and clinical decision points is also recommended and will provide an invaluable clinical resource. Recent developments in mass spectrometry mean that a candidate reference measurement procedure for PTH is now achievable and will represent major progress. Concurrently, evidence-based recommendations on clinical requirements and performance goals for PTH are required. Improving the comparability of PTH results requires support from many stakeholders but is achievable.
Catharine M
CM
Sturgeon
Stuart M
SM
Sprague
Wendy
W
Metcalfe
D006801:Humans; D007118:Immunoassay / Q000379:methods* / Q000592:standards*; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000175:diagnosis*; D010281:Parathyroid Hormone / Q000032:analysis* / Q000097:blood*
D010281:Parathyroid Hormone